Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06231238
Other study ID # 326529
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date March 2024
Est. completion date September 2025

Study information

Verified date January 2024
Source King's College London
Contact Trudie Chalder, PhD
Phone +44 (0)20 7848 0406
Email trudie.chalder@kcl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomised controlled trial aims to investigate the efficacy of a psychological intervention for long COVID (LC) / post-COVID-19 syndrome (PCS) called Balance Acceptance and Commitment Therapy (Balance ACT). The primary objective of this trial is to investigate whether Balance-ACT improves quality of life over treatment as usual (i.e., self-help leaflet) in people with PCS/LC.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 196
Est. completion date September 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 or older 2. LC/PCS diagnosis as defined by National Health Service (NHS) / National Institute for Health and Care Excellence (NICE) (i.e., symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis). A checklist will be used to ensure participants fulfil the diagnostic criteria as per the NICE guidelines 3. Ability to travel to the research site for the study assessments 4. Consent to wear a smartwatch throughout the study 5. Having registered with a General Practitioner (GP) in the United Kingdom (UK) and consent to provide their details for the study team to contact 6. Ability to provide informed consent 7. Ability to read and write English Exclusion Criteria: 1. Current diagnosis of an active major mental health disorder likely to interfere with participation 2. Unstable alcohol / drug dependency 3. Unstable complications associated with LC/PCS 4. Past hospitalisation for COVID-19 5. Current or recent participation in other treatment intervention studies (<4 weeks after completion) 6. Currently receiving psychological support or psychotherapy 7. Implanted medical devices (ie., Pacemaker/defibrillator or implanted neurostimulator/infusion device; implanted metal objects; artificial hip/knee replacement, spinal surgery; cardiac surgery requiring the placement of metal clips, valves or wires) 8. Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Balance Acceptance and Commitment Therapy
Balance-ACT is an ACT-based psychological intervention specifically designed for people with PCS/LC. Balance-ACT will use ACT techniques and mindfulness and will focus on establishing a balance psychologically and physiologically and regulating homeostasis. More specifically, Balance ACT will aim to regulate behaviours such as sleep, stress and activity, which can subsequently have an impact on homeostasis and physiology. Balance-ACT will also encourage people to live a values-based life and set goals according to their values.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
King's College London

Outcome

Type Measure Description Time frame Safety issue
Primary 36-item Short Form Health Survey (SF-36) Week 0, 14 and 20
Secondary EuroQol 5 Dimension - 5 Levels (EQ-5D-5L) Week 0, 14 and 20
Secondary Service use Week 0 and 20
Secondary Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Week 0, 7, 14 and 20
Secondary Modified Clinical Global Impressions Scale- Improvement (CGI-I) Week 0, 14 and 20
Secondary Pittsburgh Sleep Quality Index (PSQI) Week 0, 7, 14 and 20
Secondary Modified Patient Health Questionnaire-15 (PHQ-15) Week 0, 7, 14 and 20
Secondary Montreal cognitive assessment (MoCA) Week 0, 14 and 20
Secondary Perceived Deficits Questionnaire (PDQ) Week 0, 7, 14 and 20
Secondary Patient Health Questionnaire-8 (PHQ-8) Week 0, 7, 14 and 20
Secondary Generalised Anxiety Disorder-7 (GAD-7) Week 0, 7, 14 and 20
Secondary Work and social adjustment scale (WSAS) Week 0, 14 and 20
Secondary Modified DePaul Post exertional malaise questionnaire Week 0, 7, 14 and 20
Secondary Post Traumatic Stress Disorder Checklist (PCL-5) Week 0, 14 and 20
Secondary Nijmegen Questionnaire (NQ) Week 0, 14 and 20
Secondary Dyspnoea-12 Week 0, 14 and 20
Secondary Modified Medical Research Council Dyspnea Scale (mMRC) Week 0, 14 and 20
Secondary Lung function (spirometry, Resting pulse oximetry; SpO2) Week 0, 14 and 20
Secondary Muscle strength Week 0, 14 and 20
Secondary Muscle fatigue Handgrip volitional fatigue, Quadriceps non-volitional fatigue Week 0, 14 and 20
Secondary 1 minute sit-to-stand test Week 0, 14 and 20
Secondary 4 metre gait speed Week 0, 14 and 20
Secondary Short Physical Performance Battery (SPPB) Week 0, 14 and 20
Secondary International Physical Activity Questionnaire - Short Form (IPAQ-SF) Week 0, 7, 14 and 20
Secondary Heartrate variability Week 0, 7 and 14
Secondary Cognitive and Behavioural Responses Questionnaire (CBRQ) Week 0, 7, 14 and 20
Secondary Comprehensive assessment of Acceptance and Commitment Therapy processes Week 0, 7, 14 and 20
See also
  Status Clinical Trial Phase
Recruiting NCT05926505 - Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome Phase 2/Phase 3
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Completed NCT05552612 - Health-related Quality of Life and Long COVID
Completed NCT05531019 - COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A N/A
Not yet recruiting NCT04949386 - Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms. Phase 2
Recruiting NCT06118112 - Living With Long COVID: LONGCOVID-EXPERIENCE
Completed NCT05185674 - Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
Enrolling by invitation NCT05965739 - RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms N/A
Enrolling by invitation NCT05965752 - RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms N/A
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT05606211 - Pain in Long COVID-19: The Role of Sleep
Active, not recruiting NCT05713266 - Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
Completed NCT05601180 - Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID. N/A
Completed NCT05679505 - Vagus Nerve Stimulation for Post-COVID Syndrome N/A
Not yet recruiting NCT06045338 - Mind Body Intervention for Long COVID N/A
Recruiting NCT06091358 - Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation. N/A
Recruiting NCT05566392 - Longterm Influence of Pediatric Long COVID Syndrome
Recruiting NCT05855369 - Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss Phase 2/Phase 3
Recruiting NCT05572346 - Digital App for Telerehabilitation in Respiratory Diseases
Recruiting NCT06316843 - Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 Phase 2